0001209191-20-049554.txt : 20200903 0001209191-20-049554.hdr.sgml : 20200903 20200903184131 ACCESSION NUMBER: 0001209191-20-049554 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200901 FILED AS OF DATE: 20200903 DATE AS OF CHANGE: 20200903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chaubey Alka CENTRAL INDEX KEY: 0001821605 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38613 FILM NUMBER: 201160288 MAIL ADDRESS: STREET 1: C/O BIONANO GENOMICS, INC. STREET 2: 9540 TOWNE CENTRE DRIVE, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bionano Genomics, Inc CENTRAL INDEX KEY: 0001411690 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 261756290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9540 TOWNE CENTRE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 888-7600 MAIL ADDRESS: STREET 1: 9540 TOWNE CENTRE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: BioNano Genomics, Inc DATE OF NAME CHANGE: 20120703 FORMER COMPANY: FORMER CONFORMED NAME: BioNanomatrix Inc DATE OF NAME CHANGE: 20070906 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2020-09-01 2020-09-03 0 0001411690 Bionano Genomics, Inc BNGO 0001821605 Chaubey Alka C/O BIONANO GENOMICS, INC. 9540 TOWNE CENTRE DRIVE, SUITE 100 SAN DIEGO CA 92121 0 1 0 0 Chief Medical Officer Stock Option (Right to Buy) 0.56 2020-09-01 4 A 0 300000 0.00 A 2030-09-01 Common Stock 300000 300000 D 25% of the shares subject to the stock option vest and become exercisable on August 31, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such applicable vesting date and the terms of the Issuer's 2020 Inducement Plan. The Form 4 is being amended for the sole purpose to change a typographical error in the exercise price of derivative security in column 2 of Table II. /s/ R. Erik Holmlin, Attorney-in-Fact 2020-09-03